Vitasora Health Limited · ASX:VHL
Vitasora Health — Corporate Update (June 2021)
23 slides from Vitasora Health's corporate update, Jun 23, 2021
Slide 1: Investor Update
Investor Update By Marjan Mikel Date 23/6/2021
Slide 2: Commercial Update
COMMERCIAL UPDATE OTC CLASS II FDA TGA & CE $12.5 MILLION CAPITAL ORG STRATEGY & APPROVAL RAISE OPERATIONS wheezo is TGA Class I Medical RE-ENGINEERED device and is registered in the Agnostic indication allowing both ARTG, 327306 with CE Mark Successful completion of an prescription reimbursement an
Slide 3: Asthma is sub-optimally managed
ASTHMA IS SUB-OPTIMALLY MANAGED For patients and physicians, there are limited options that allow for digitised, objective and holistic monitoring of asthma management once a patient leaves the care of health care practitioners ASTHMA IN AUSTRALIA ASTHMA MANAGEMENT CHALLENGES 2.7M(11.2%) affected 1
Slide 4: Current disease management is inadequate
CURRENT DISEASE MANAGEMENT IS INADEQUATE DAY 1 3/6/9/12 MONTHS Patient presents to Subjective their GP with Scheduled Subjectivity in determining Asthma symptoms Asthma PATIENTS OUT OF THE CLINIC symptomology that is used to appointments classify asthma severity AND IN THE HOME SETTING Memory relian
Slide 5: Meet wheezo
meet wheezo Developed in Australia, wheezo is designed to assist with asthma management. The wheezo device • The small handheld device is easy to use, portable, non-invasive and child-friendly • wheezo includes a device and app that records and analyses 30 seconds of breath sounds for the presence o
Slide 6: Meet wheezo: the eHealth app
meet wheezo Developed in Australia, wheezo is designed to assist with asthma management. Analyses breath Records triggers*, sounds for the symptoms* and presence of wheeze medication use* The eHealth App Provides local weather Digitises an Asthma information, including Action Plan and allows pollen
Slide 7: Meet wheezo: the HCP portal
meet wheezo Developed in Australia, wheezo is designed to assist with asthma management. The HCP portal Allows users to set reminders and track View their asthma summary and history for a medication compliance clearer picture of their asthma Health Care Professional’s (HCPs) can use the data collect
Slide 8: How wheezo works
HOW WHEEZO WORKS Example recordings shown below Breath sound recording wheezo® is constructed like a stethoscope Figure A and records breathing sounds for analysis and shows the amplitude of the recording and eight breath cycles can be seen as future review. the waxing and waning of the sound amplit
Slide 9: OTC Class II FDA approval for wheezo
OTC CLASS II FDA APPROVAL FOR wheezo This allows Respiri more channel options to explore in the USA including • Class II Medical Device opening up reimbursement possibilities • CPT Reimbursement Codes for Remote Patient Monitoring (RPM) physician prescription • Pharmacy/Retail channels without presc
Slide 10: Reimbursement opportunity
REIMBURSEMENT OPPORTUNITY A US patient generates up to 5 x the annual revenue of an Australian patient, with little or no out of pocket expense, unlike Australia. 2021 Payment Rates 1 2 3 Provider sets p a t i e nt u p on Physiological data Data sent in real time & clinical a remote mo n i t o r i n
Slide 11: Upcoming research & programs
UPCOMING RESEARCH & PROGRAMS CLINICAL VALIDATION ASTHMA DATABASE 1. Comparison of the wheeze rate algorithm with Respiri is looking to increase the asthma-related data expert analysis*. Submitted to European Respiratory points tracked by integrating: Society (ERS). Accuracy 91% Sensitivity 87% Speci
Slide 12: Integrated respiratory digital management platform
Integrated respiratory digital management = differentiated reimbursed, value add remote patient monitoring platform Adherium offer acceptance deadline July 16. End the process one way or the other Algorithm enhancement For monitoring effective Administration Propeller Health/ResMed Adherium Unique P
Slide 13: 1,600 pharmacies onboarded & more scheduled
1,600 PHARMACIES ONBOARDED & MORE SCHEDULED PHARMACIES STOCKING WHEEZO 13
Slide 14: wheezo pharmacy sales cycle
WHEEZO PHAMRACY SALES CYCLE 14
Slide 15: Key Activities Update – Pharmacy Platform
Key Activities Update – PHARMACY PLATFORM Pharmacy Platform Professional Services program begins roll-out in Catalyst stores Professional Services program rolled out to: - Catalyst Stores (24/5) - Chemist Discount Centres (8/6) - Advantage Pharmacies (8/6) - Roll out to TerryWhite Chemmart August 1
Slide 16: Key Activities Update - CC in-pharmacy asthma clinic
Key Activities Update - CC in-pharmacy asthma clinic Overview of pilot and estimated timelines 1. Phcy Program Set-up 2. Phcy Prep 3. Clinic Set-up 4. Follow-up 2-6 wks before clinic 1 wk before clinic Clinic Days 1 wk after clinic (31/5 – 20/6) (21/6-25/6) (5/7- 12/7) (13/7-19/7) wheezo Nurse asthm
Slide 17: Pharmacy & physician engagement programs
PHARMACY & PHYSICIAN ENGAGEMENT PROGRAMS Connected Care Activities ▪ A total of 183 contacts have been made to pharmacies in May, an increase from last month of nearly 60% ▪ Therefore, CC are again reverting to the proactive call approach, cold calling stores from the most recent TO report and email
Slide 18: Program very well received by pharmacy
Program very well received by PHARMACY Feedback from CC Training: ▪ As part of the CC measure of effectiveness, feedback is sought from participants of the training sessions provided ▪ To date there have been 153 responses (since launch of feedback process) Key highlight - CC training is crucial and
Slide 19: Key Activities Update TWC Catalogue
Key Activities Update TWC Catalogue May 27- June 18 1.6M TWC Loyalty Club Members
Slide 20: Key Activities Update APP Conference 2021
Key Activities Update APP Conference 2021 (20-23 May) Ruth trained over 100 attendees at the Cipla stand: • Recorded 12 new leads for independents • This has resulted in 5 new stockists come July 1 wheezo presents Michael Clarke at APP • Guest speaker in the main auditorium • Photo opportunities for
Slide 21: Questions
QUESTIONS 21
Slide 22: Forward Looking Statements
FORWARD LOOKING STATEMENTS Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri’s current expectations, estimates and projections about the industry in which Respiri operates, and its be
Slide 23: Respiri Limited risk factors
RESPIRI LIMITED (THE COMPANY) RISK FACTORS This report identifies some of the major risks associated with an investment in the Company. The risk factors below ought not to be taken as exhaustive of the risks faced by the Company or by investors in the Company. Speculative nature of investment An inv